-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150

Benzinga·06/11/2026 12:24:40
Listen to the news
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $140 to $150.